Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
about
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesRegulation of glucose homeostasis by GLP-1Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophoreRole of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationAlogliptin benzoate for management of type 2 diabetesAlogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.Diabetes treatment in patients with renal disease: Is the landscape clear enough?Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Alogliptin: a new addition to the class of DPP-4 inhibitors.Clinical pharmacokinetics and pharmacodynamics of linagliptin.Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptinDietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents.Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research.New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.Alogliptin.Alogliptin benzoate for the treatment of type 2 diabetes.Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Linagliptin: from bench to bedside.DPP-4 inhibitors: pharmacological differences and their clinical implications.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathwaysCharacterization of the post-prandial insulinemic response and low glycaemic index of a soy beverage.Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
P2860
Q24288949-5DEE056A-1E88-491A-B38D-F6864C375EA4Q24563430-CE7C411D-AA5F-4CCA-8BFB-58036AEE61A5Q24569706-09291C73-6596-48FD-96A7-346F10249331Q26778329-EE03CF7A-88E6-4AE3-87FE-3C166F2C08BDQ28083933-EB255DA8-F8F0-4781-84F3-05EA885080C5Q33874654-1A9254C3-D581-49C9-903F-104506745C52Q34068430-2B88236B-5CA6-4EB6-903A-3B5B24A7EA52Q34139048-CDE44518-3937-4BE0-B081-487981CD3DBDQ34620671-A4992C76-51A3-42EF-96E1-BEA84DF88956Q34638128-4B54BEC0-2DCA-4444-9E93-EFDAA48BAEC0Q35026483-22C9CA37-C7B1-4057-9D13-BE0AB0BEA4A4Q36706802-DD8128EE-A4C4-4E6F-97FB-0BECAC84F048Q36976985-02613D8A-1390-4ADE-B642-35F6E1A47D10Q37067760-1A6604FF-BCC2-4AB4-969E-74F856DD3C74Q37735838-B0826C20-720A-47D4-999C-5183D2113D0AQ37780914-EE2FD49C-BA37-4E82-B87D-8086A93E7B29Q37866299-C2F01715-18CB-425C-BBC7-87F193F4813BQ37878396-CB68C823-E057-489E-B435-43BDC83DBD10Q37910902-9A20FF4B-DDAB-421F-8667-A4A670F62838Q38012068-59031E5F-2E1C-4DB2-BE98-C28777F62714Q38017726-250B2025-0A9F-48D4-BCCD-326D56099A00Q38040596-CDF8DF4C-50AB-4DE8-97E6-60E42E69B9D4Q38058463-DA8643B6-BB23-46FD-9C82-555B0656EA59Q38167010-1D0709C8-C4C3-45E5-8A38-A4BDA247ADD2Q38178240-69B09F60-7F66-4167-AAE7-7C8B4966350FQ38197275-C562C0B9-9CB2-4CA4-A7F6-AD0BEB7DBFBEQ38200670-5E898A71-0F9B-4DC6-9347-88838E63C97AQ38205588-97002B95-53DD-406E-9544-8D1DBD8C95E1Q38213703-C0D0B9EA-A0BE-48BE-80A5-1EAFC2C13759Q38244576-868F390A-5929-4A20-97F5-9822DA23D30CQ38412153-255E50BB-ADFE-4A2F-9CE4-0AABCF072E99Q38455771-1E6B6BBD-2CEB-4DBF-A9CB-20023AEA8AECQ38541323-F893E785-6FE0-4C84-A8E5-162E854BEEE0Q38546981-4D8C2833-925A-4F37-80A4-EC3458B5487FQ38556037-34C9A113-B76C-4E92-BB3E-B38DAB470437Q38647717-B51A15F3-7E34-45B7-B4F4-F588E9EC00A8Q40652421-556F6EFA-3A90-452E-A27C-1A1670965A9CQ41326923-0F71E54E-2AC4-4330-BDE7-CDE47FEB0274Q42723596-32B7DD4D-9C5F-458E-B29C-6B85EB56610DQ42987834-0EF21092-21DF-47C1-9E28-DC499F329144
P2860
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacokinetics, pharmacodyna ...... ptin in healthy male subjects.
@ast
Pharmacokinetics, pharmacodyna ...... ptin in healthy male subjects.
@en
type
label
Pharmacokinetics, pharmacodyna ...... ptin in healthy male subjects.
@ast
Pharmacokinetics, pharmacodyna ...... ptin in healthy male subjects.
@en
prefLabel
Pharmacokinetics, pharmacodyna ...... ptin in healthy male subjects.
@ast
Pharmacokinetics, pharmacodyna ...... ptin in healthy male subjects.
@en
P2093
P1476
Pharmacokinetics, pharmacodyna ...... ptin in healthy male subjects.
@en
P2093
Aziz Karim
Elisabeth R Wann
Michael Davenport
Paul Covington
Penny Fleck
Qais A Mekki
Ronald Christopher
P304
P356
10.1016/J.CLINTHERA.2008.03.005
P577
2008-03-01T00:00:00Z